---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-219539"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2023-08-24T23:59:59+00:00"
generated_at: "2026-06-11T04:30:32.270086+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Teva settles DOJ price-fixing charges with $225M fine, DPA; avoids federal exclusion

## Summary
- Teva enters Deferred Prosecution Agreement with DOJ over 2020 price-fixing charges for generic drugs.
- Fine of $225M payable over 5 years: $22.5M/yr 2024-2027, $135M in 2028.
- Teva to donate $50M of two generic products (at wholesale cost) and divest one generic product.
- Admits a single former employee engaged in three instances of collusion with competitors (2013-2015).
- DPA term is 3 years; upon compliance and payment, charges dismissed with prejudice.

## SEC filing metadata
- accession: 0001193125-23-219539
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2023-08-24T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000119312523219539/0001193125-23-219539-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000119312523219539/d479429d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-219539
- JSON: https://secwatch.observer/filing/0001193125-23-219539.json
- Plain text: https://secwatch.observer/filing/0001193125-23-219539.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.